SAN DIEGO & GOLETA, Calif.–(BUSINESS WIRE)–$INGN #ClassAction–Shareholder rights law firm Robbins Arroyo LLP reminds investors that shareholders of Inogen (NASDAQ: INGN) filed a class action complaint against the company for alleged violations of the Securities Exchange Act of 1934 between November 8, 2017 and February 26, 2019. Inogen is a medical technology company that primarily develops, manufactures, and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients.
If you suffered a loss as a result of Inogen’s misconduct, click here.
Inogen, Inc. (INGN) Accused of Misstating its Strong Sales and Financial Success
According to the complaint, on November 7, 2017, Inogen touted its strong sales and financial success, predicting “strong results in 2018…” and increased its guidance range for full year 2017 revenue. Inogen subsequently increased its FY18 guidance range, emphasizing that the company’s strong direct-to-customer sales were the result of the strong sales acumen of its salesforce. These quarterly statements were often followed by significant increases in stock price that resulted in a class period high of more than $282 per share on September 14, 2018. In February 2019, a series of news articles were released criticizing the company’s narrative and denouncing its sales tactics, negatively affecting the company’s stock. Then, on February 26, 2019, Inogen announced poor 4Q18 and FY18 financial results, which caused Inogen’s stock to fall nearly $34 per share, or more than 24% to close at $106.28 per share on February 27, 2019. The stock now trades at around $46 per share, representing another 57% decline in value.
Inogen, Inc. (INGN) Shareholders Have Legal Options
Contact us to learn more:
Leo Kandinov
(800) 350-6003
lkandinov@robbinsarroyo.com
Shareholder Information Form
Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. Click Here to receive free alerts from Stock Watch when companies engage in wrongdoing.
Attorney Advertising. Past results do not guarantee a similar outcome.
Contacts
Leo Kandinov
Robbins Arroyo LLP
5040 Shoreham Place
San Diego, CA 92122
LKandinov@robbinsarroyo.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsarroyo.com
Company earns recertification, validating commitment to strong cybersecurity protecting sensitive dataBALTIMORE--(BUSINESS WIRE)--Real Time Medical Systems…
Annual User Conference and Innovation Challenge Designed to Pioneer the Future of Digital Health and…
Company earns recertification, validating commitment to strong cybersecurity protecting sensitive dataBALTIMORE--(BUSINESS WIRE)--Real Time Medical Systems…
Annual User Conference and Innovation Challenge Designed to Pioneer the Future of Digital Health and…
Calgary, Alberta--(Newsfile Corp. - June 11, 2024) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE:…
Findable research is fundable research BOSTON, June 11, 2024 /PRNewswire/ -- OpenScholar announced immediate availability of…